Servier Chooses Tripos as Chemistry Partner in Search for New Drugs.

ST. LOUIS -- Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, and Servier, the largest independent French pharmaceutical company, have announced they will work together to identify potential drugs. Terms of the agreement were not

Servier successfully identified and subsequently validated therapeutic compounds from Tripos' LeadQuest(R) compound collection. Based on these important results, Servier has now chosen to partner with Tripos to further design and synthesize compounds for potential drug development. Tripos will employ its ChemSpace(R) and LeadHopping(R) proprietary technologies and integrated knowledge-driven chemistry processes to identify additional novel chemistries against the same targets. Tripos' ChemSpace technology is used to quickly identify similar but distinct chemical entities, while its LeadHopping technology helps scientists navigate the patent space.

"Servier has earned an impressive reputation for research, and to be chosen as their partner is an honor for our Tripos team," said Dr. Mark Allen, senior vice president and managing director of Tripos Discovery Research, Ltd. "By applying our proprietary chemistry processes, Servier will be able to identify potential leads much sooner, therefore accelerating the research process. We hope the success we generate through this drug discovery project will lay the foundation for future Tripos and Servier partnerships and developments."

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects," "anticipates," "projects," "estimates," "intends," "plans," "believes," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.